Figure 4.

Co-inhibition of ALK4 and 5 in combination with MAPK blockade increases ¹²⁴I uptake in Braf mice. (A) Schema for mouse experiments testing effects of CKI and/or EW7197 or follistatin on ¹²⁴I incorporation into thyroid tumors from the indicated mouse models. (B) Fold-change in maximum ¹²⁴I uptake in Braf and Braf/TβR1 mice treated with CKI, EW7197 or follistatin or the indicated combinations (*P < 0.05, **P < 0.01). (C and D) Quantitative RT-PCR (C) and Western blots (D) of tumor tissues from B (collected after second ¹²⁴I PET study). (E) Immunofluorescent staining for NIS and pan-cadherin in tumors from mice treated as indicated in (A).